This would be a break through in psychiatry especially for those who are treatment refractory to medications or those who cannot tolerate the drugs due to intolerable side effects. Often patients that are treatment refractory have to go through ECT, Psychotropic Drugs, Vagus Nerve Stimulation, TMS and other treatments that are alternative therapies.
Neuroscientists at the Center for Addiction and Mental Health (CAMH) have developed a protein peptide that may be a novel type of highly targeted treatment for depression with a low side-effect profile. Depression affects one in ten Canadians at some time in their lives and is a leading cause of disability worldwide.
The study published in this month's Nature Medicine found that coupling between two dopamine receptors was significantly elevated in the brains of people who had been diagnosed with major depression. "We identified a potential therapeutic target for development of novel anti-depressants." said Dr. Fang Liu, Principal Investigator and Senior Scientist in CAMH's Neuroscience Program and Associate Professor of Psychiatry at the University of Toronto. Working from this discovery, researchers sought to find a way to disrupt coupling between the two receptors in hopes that it would have an anti-depressant effect.
Click to read the entire article: Treatment Refractory Depression
This article is for informational purposes only and not to be used to diagnose or treat any mental illness